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                                             ABSTRACT
The purpose  of  this  research  was  to  prepare  controlled  release  tablets  of  Fluconazole  in
reducing the dose and increasing efficiency with reducing fluctuations.By controlling the rate
of  release  the  side  effects  such  as  hallucinations  and  paranoid  behaviour  will  also  be
minimized.A 22 factorial  design  was  employed  to  optimize  the  formulations,producing  4
factorial  points,this  design  generally  involves  dependent  variables  Y,independent  variable
X.The  independent  variable  selected  for  this  study  were  (X1-X4),X1amount  of
maltodextrin,X2  amount  of  Carbopol  940,  X3  amount  of  HPMC,X4  amount  of  Ethyl
cellulose.The dependent variable were (Y1-Y4),Y1 hardness,Y2 amount of drug release at 1st
hour, Y3 time taken to reach t50%, Y4 Zone of inhibition.Controlled release release tablets
have  been  prepared  incorporating  antifungal  drug  Fluconazole  using  polymers  like
Maltodextrin,HPMC,Carbopol 940,Ethyl Cellulose.The anti microbial studies showed good
antifungal activity based on zone of inhibition.The invitro drug release studies  revealed that
as the concentration of polymer increased the drug release decreased.Formulations containing
higher concentration of polymers were able to efficiently control Fluconazole release over a
time period of 8hrs.The formulations containing 2:2 ratio of polymers gave the  best results,
among which the formulation containing Carbopol-940:HPMC with 2:2 ratio of polymers is
concluded  as  best  formulation  in  terms  of  required  drug  release  in  a  controlled  release
manner. The drug release mechanism was confirmed as case-II transport or typical zero-order
release.IR spectra matching confirmed that there was no major interaction between the drug
and the excipients used.
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                                                                                    INTRODUCTION
                                           INTRODUCTION
  CONTROLED RELEASE DRUG ADMINISTRATION:
During the last two decades there has been remarkable increase in interest in controlled
release drug delivery system1. This has been due to various factor viz. the prohibitive cost
of developing new drug entities,  expiration of existing international patents, discovery of
new polymeric materials suitable for prolonging the drug release, and the improvement in
therapeutic efficiency and  safety achieved  by these delivery systems.  Now-a-days  the
technology of controlled release is also being applied to veterinary products.
  Modified Release Dosage Forms2: According to the United States Pharmacopoeia the term
'modified release dosage forms' is used to denote the dosage forms for which the drug release
characteristics of time course and/or location are chosen to accomplish therapeutic objectives
not offered by the conventional dosage forms. Two types of modified release dosage forms
are recognised.
1] Extended release dosage forms:
It is defined as the one that allows at least a two fold reduction in the dosing frequency
as compared to that of conventional dosage form.
2] Delayed release dosage forms:
It is defined as one that releases the drug at a time other than “immediately” after
administration.
Rationale of controlled drug delivery3
The basic rationale for controlled drug delivery is  to  alter the  pharmacokinetics and
pharmacodynamics of pharmacologically active moieties by using novel drug delivery system
or by modifying the molecular structure and /or physiological parameters inherent in a
  selected route of administration.
  Different terminologies have been used for the new drug delivery system by
  different  authors.
A] Controlled Action:
In this type of dosage forms it provides a prolonged duration of drug release with
predictability and reproducibility of drug release kinetics. In this case, the rate of drug
absorption is equal to the rate of drug removal from body.
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2] Sustained Action:
In this type of dosage forms, a sufficient amount of drug is initially made available to the
body to  cause a desired  pharmacological  response. The remaining fraction  is  released
periodically and is required to maintain the maximum initial pharmacological activity for
some desirable period of time in excess of time expected from usual single dose.
3] Prolonged Action:
These types of dosage form are designed in such a way that it release the drug over an
extended period during which pharmacological response is obtained but does not necessarily
maintain the constant blood level.
4] Site specific and receptor release:
It refers to targeting of drug directly to a certain biological location.
   
  Potential advantages and disadvantages of controlled release dosage forms :
Advantages 4-7:
i] Patient Compliance:
Lack of compliance is generally observed with long term treatment of chronic disease, as
success of drug therapy depends upon the ability of patient to comply with the regimen.
Patient  compliance is  affected  by a combination of several  factors, like  awareness of
disease process, patient  faith in therapy, his understanding of the need to  adhere to a
strict  treatment  schedule.   Also  the complexity of therapeutic regimens,  the cost  of
therapy and magnitude of local and or systemic side effect of the dosage form.
 The problem of lack of patient compliance can be resolved to some extent by administering
 controlled release drug delivery system.
ii] Reduced 'see- saw' fluctuation:
Administration of a drug in a conventional dosage form [except via intravenous infusion at a
constant  rate] often  results  in  'see –  saw' pattern of drug  concentration in  the systemic
circulation and tissue compartments.  The magnitudes of these fluctuations depend on drug
kinetics such as the rate of absorption, distribution, elimination and dosing intervals. The
'see-saw' or 'peak and valley'  pattern is more striking in  case of drugs  with biological half
lives of less than four hours, since prescribed dosing intervals are rarely less than four hours.
A  well  designed  controlled  release  drug delivery system  can  significantly reduce the
frequency of drug dosing  and  also  maintain  a more steady drug  concentration  in  blood
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circulation and target tissue cells.
iii] Reduced total dose:
Controlled release drug delivery systems have repeatedly been shown to use less amount of
total drug to treat a diseased condition. By reducing the total amount of drug, decrease in
systemic or local side effects are observed. This would also lead to greater economy.
  iv] Improved efficiency in treatment:
Optimal therapy of a disease requires an efficient delivery of active drugs to the tissues,
organs that need treatment. Very often doses far in excess to those required in the cells have
to be administered in order to achieve the necessary therapeutically effective concentration.
This unfortunately may lead to undesirable, toxicological and immunological effects in non-
target tissue. A controlled release dosage forms leads to better management of the acute or
chronic disease condition.
Disadvantages5-7 : 
i) Dose dumping:
Dose dumping is a phenomenon where by relatively large quantities of drug in a controlled
release formulation is rapidly released, introducing potential toxic quantities of the drug into
the systemic circulation. Dose dumping can lead to fatalities in  case of potent drug, which
have a narrow therapeutic index.
e.g: Phenobarbital.
 ii) Less flexibility in accurate dose adjustment:
In conventional dosage forms, dose adjustments are much simpler e.g. tablet can be divided
into two fractions. In case of controlled release dosage forms, this appears to be much more
complicated. Controlled release property may get lost, if dosage form is fractured.
  iii) Poor In vitro – In vivo correlation:
In controlled release dosage form, the rate of drug release is deliberately reduced to achieve
drug release possibly over a large region of gastrointestinal tract. Here the so called
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 ‘Absorption window’ becomes important and may give rise to unsatisfactory drug absorption
in vivo despite excellent in-vitro release characteristics.
iv) Patient variation:
The time period required for absorption of drug released from the dosage form may vary
among individuals. Co-administration of other drugs, presence or absence of food and
residence time in gastrointestinal tract is different among patients. This also gives rise
to variation in clinical response among the patient.
     Fig.1: Controlled release drug delivery system
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  Criteria to be met by drug proposed to be formulated in controlled release
  dosage  forms5,6:
  a) Desirable half-life.
b) High therapeutic index
c) Small dose
d) Desirable absorption and solubility characteristics.
e) Desirable absorption window.
f) First past clearance.
 DESIGN AND FORMULATION OF ORAL CONTROLLED RELEASE DRUG
DELIVERY SYSTEM AND THE FACTORS AFFECTING THEREOF7-10:
The oral route of administration is the most preferred route due to flexibility in dosage form,
 design and patient  compliance. But here one has to take into consideration, the various
pH     that the dosage form would encounter during its transit, the gastrointestinal motility,
the  enzyme system and its influence on the drug and  the dosage form. The majority of
oral  controlled  release systems  rely on dissolution, diffusion or a combination of both
mechanisms, to generate slow release of drug to the gastrointestinal milieu.
 Theoretically and desirably a controlled  release delivery device, should release the
drug by a  zero-order process which would result in a blood-level time profile similar
to that after intravenous constant rate infusion.
 Plasma drug concentration-profiles for conventional tablet or capsule formulation, a
sustained      release formulation, and a zero order controlled release formulation.
      Controlled (zero-order) drug  release has  been  attempted to  be achieved,  by
following classes of controlled drug delivery system8.
     A)Diffusioncontrolledsyste
m 
  i) Reservoir type.
ii) Matrix type
B) Dissolution controlled system.
i) Reservoir type.
ii) Matrix type
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C) Methods using Ion-exchange.
D) Methods using osmotic pressure.
E) pH independent formulations.
F) Altered density formulations
  Drug properties influencing the design of sustained or controlled release drug delivery
  system  are classified as :
1] Physicochemical properties of the drug
These include dose size, aqueous solubility, protein binding, molecular size, drug stability and
partition coefficients.
2] Biological factors
These include absorption, distribution, metabolism, duration of action, margin of safety, side
effects of drug, disease state and circadian rhythm.
Methods to achieve oral controlled drug delivery8:
 There are various methods employed for the fabrication of oral controlled release delivery
systems. Ritschel has given a detailed report of these techniques. These are as follows.
a.  Hydrophilic matrix
b. Plastic matrix
c.  Barrier resin  beads
d. Fat embedment
e. Repeat action
f. Ion exchange resin
g.  Soft gelatin depot  capsules
h. Drug complexes
  Evaluation of controlled release Tablets:
Before marketing a controlled release product, it is must to assure the strength, safety,
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stability and reliability of a product by forming in-vitro and in-vivo analysis and correlation
between the two. Various authors have discussed the evaluating parameters and procedures
for controlled release formulations.
1. In – Vitro Methods
These are:-
a. Beaker method
b. Rotating disc method
c. Rotating Bottle method d.
d .Rotating Basket method
e.  Stationary Basket  Method
f. Oscillating tube method
g. Dialysis method
h. USP dissolution method.
2. In–Vivo Methods
Once the satisfactory in-vitro profile is  achieved, it becomes necessary to  conduct in-vivo
evaluation and establish in-vitro in-vivo correlation. The various in-vivo evaluation methods
are:-
a.  Clinical  response
b. Blood level data
c.  Urinary excretion  studies
d. Nutritional studies.
e. Toxicity studies
f. Radioactive tracer techniques
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FACTORIAL DESIGN11-14  :
Factorial design is  an important method to determine the effects of multiple variables on a
response. Traditionally,  experiments  are designed to determine the effect of ONE variable
upon ONE response. R.A. Fisher showed that there are advantages by combining the study
of  multiple variables  in  the same factorial  experiment.  Factorial  design can  reduce the
number of experiments  one has  to  perform  by studying multiple factors simultaneously.
Additionally, it  can be used to  find both main  effects (from each independent  factor) and
interaction  effects  (when both  factors  must  be used  to  explain  the outcome).  However,
factorial design can only  give relative values,  and to  achieve actual numerical values the
math becomes difficult,  as regressions (which require minimizing a sum of values) need to
be performed. Regardless, factorial design is a useful method to design experiments in both
laboratory and industrial settings.
 Factorial design tests all possible conditions. Because factorial design can lead to a
large number of trials, which can become expensive and time-consuming, factorial
design  is  best  used  for a small  number of variables  with  few states  (1  to  3).
Factorial  design works well when interactions between variables  are strong and
important and where every variable contributes significantly.
 Factorial Designs are used in experiments where the effects of different  factors, or
conditions, on  experimental  results  are to  be elucidated.some practical  examples
where  factorial  designs are optimal  are experiments  to  determine the effect  of
pressure and lubricant on the hardness of a tablet formulation, to determine the efect
of disintegrant and lubricant concentration on tablet dissolution, or to determine the
efficacy of a combination of two  active ingredients in  an  over-the-counter cough
preparation.
   Factorial designs are the designs of choice for simultaneous determination of the
effects of several factors and their interactions.
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Introduction to Design of Experiments (DOE) - DOE Types
       The design  and  analysis of experiments  revolves around the understanding of the
effects 
     of  different variables on other variable(s).
 In mathematical jargon, the objective is to establish a cause-and-effect relationship
          between  a number of independent variables and a dependent variable of interest.
         The dependent variable, in the context of DOE, is called the response, and 
          the  independent variables are called factors.
 Experiments  are run  at  different  factor values, called levels.  Each  run  of an
experiment involves a combination of the levels of the investigated factors. Each of
the combinations is  referred to as a  treatment. In a single factor experiment,  each
level of the factor is referred to as a treatment.
 In experiments with many factors,  each combination of the levels of the factors is
referred to as a treatment. When the same number of response observations are taken
for each of the treatments of an experiment, the design of the experiment is said to be
balanced.  Repeated  observations  at  a given  treatment  are called replicates.  The
number of treatments of an  experiment is determined on the basis of the number of
factor levels being investigated in the experiment.
 For example, if an experiment involving two factors is to be performed, with the first
factor  having  x levels  and  the second  factor having  z  levels,  then  x z  treatment
combinations can possibly be run, and the experiment is an x z factorial design.
 If all x z combinations are run, then the experiment is a full factorial. If only some of
the xz treatment combinations are run, then the experiment is a fractional factorial.
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 In  full  factorial  experiments,  all  of the factors  and  their interactions  are investigated,
whereas in fractional factorial experiments, all interactions are not considered because not all
treatment combinations are run.
 It can be seen that the size of an experiment escalates rapidly as the number of factors,
or the number of the levels of the factors, increases. For example, if two  factors  at
three levels each  are to  be used,  nine different  treatments  are required  for a full
factorial experiment (3 3 = 9). If a third factor with three levels is added, 27 treatments
are required (333 = 27)  and 81 treatments  are required if a fourth  factor with three
levels is added (3333 = 81). If only two levels are used for each factor, then in the four
factor case,  16  treatments  are required  (2  2  2  2= 16).  For this  reason,  many
experiments  are restricted  to  two  levels.  Fractional  factorial  experiments  further
reduce the number of treatments to be executed in an experiment.
DOE Types
The following is a summary of some of the most common DOE types.
1 One Factor Designs
These are the designs where only one factor is under investigation, and the objective is to
determine whether the response is significantly different at different factor levels. The factor
can be qualitative  or quantitative. In the case of qualitative factors  (e.g.  different suppliers,
different  materials,  etc.), no  extrapolations  (i.e.  predictions)  can  be performed outside the
tested levels, and only the effect of the factor on the response can be determined. On the other
hand, data from tests where the factor is quantitative (e.g. temperature, voltage, load, etc.) can
be used for both effect investigation and prediction, provided that sufficient data are
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available.  2 Factorial Designs
In factorial designs, multiple factors are investigated simultaneously during the test. As in
one factor designs, qualitative and/or quantitative factors can be considered. The objective of
these designs is to identify the factors that have a significant effect on the response, as well as
investigate the effect of interactions (depending on the experiment design used). Predictions
can  also be performed  when quantitative factors  are present, but  care must be taken since
certain designs  are very limited in the choice of the predictive model. For example, in two
level designs only a linear relationship between the response and the factors can be used,
which may not be realistic.
General Full Factorial Designs
In general full factorial designs, each factor can have a different number of levels, and the
factors can be quantitative, qualitative or both.
Two Level Full Factorial Designs
These are factorial designs where the number of levels for each factor is restricted to two.
Restricting the levels to two and running a full factorial experiment reduces the number of
treatments (compared to a general full factorial experiment) and allows for the investigation
of all the factors and all their interactions.
If all factors are quantitative, then the data from such experiments can be used for predictive
purposes, provided a linear model is appropriate for modeling the response (since only two
levels are used, curvature cannot be modeled).
Two Level Fractional Factorial Designs
This is a special category of two level designs where not all factor level combinations are
considered and the experimenter can choose which combinations are to be excluded. Based
on the excluded combinations, certain interactions cannot be determined.
   
  Plackett-Burman Designs
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This is a special category of two level fractional factorial designs, proposed by R. L. Plackett
and J. P. Burman, where only a few specifically chosen runs are performed to investigate just
the main effects (i.e. no interactions).
Taguchis Orthogonal Arrays
Taguchis orthogonal arrays are highly fractional designs, used to estimate main effects using
only a few experimental runs. These designs are not only applicable to two level factorial
experiments, but also can investigate main effects when factors have more than two levels.
Designs are also available to investigate main effects for certain mixed level experiments
where the factors included do not have the same number of levels.
  3 Response Surface Method Designs
  These are special designs that are used to determine the settings of the factors to achieve 
   an optimum value of the response.
4 Reliability DOE
This is a special category of DOE where traditional designs, such as the two level designs, are
combined with reliability methods to investigate effects of different factors on the life of a
unit. In Reliability DOE, the response is a life metric (e.g. age, miles, cycles, etc.), and the
data may contain censored observations (suspensions, interval data). One factor designs and
two level factorial designs (full, fractional, and Plackett-Burman) are available in DOE++ to
conduct a Reliability DOE analysis.
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 Optimization techniques in Pharmaceutical formulation and processing15-19  :
First of all it is necessary to understand the meanings of “Optimization”. “to optimize” is to
make as much perfect as possible. It is the process of obtaining optimum formulation.
     According to Merriam Webster Dictionary Optimization means,”an act,or methodology of
making something (as a design,system,or decision) as fully perfect,functional,or effective as
possible;specifically : the mathematical procedures”. Optimization techniques are the research
analytical tools for a problem which are available to a researcher.These problems are related to
pharmaceutical  formulation,composition  of  the  delivery  system  and  process  design.These
involve  mostly  mathematical  techniques  in  novel  drug  delivery  systems.  In  Mathematics,
optimization is the process of obtaining of maxima or minima.In most of the cases, Lagrangian
method of  optimization has  been  used  for  solving problems.There are certain  variables  in
optimization techniques regarding Pharmaceutical formulations:
These variables are of two types:
1.Independent variables
2.Dependent variables
Fig:2-  Response Surface in  Optimization  techniques  of Pharmaceutical  formulation  and
processing
There are two  types  of problem  which  are usually addressed  in  the optimization
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techniques:
1. Unconstrained
2. Constrained
  
Fig :3-Types of problems in optimization 
 Methods for Optimization techniques:
Several methods can be of use in Applied optimization:
1. Evolutionary operations
2. The Simplex methods
3. The Lagrangian Method
4. Search Method
 5. Canonical Analysis
   Forms of Optimization techniques:
There are three forms of systematic optimization techniques
Dept of Pharmaceutics, KMCH College of Pharmacy, Coimbatore    Page | 14
                                                                                    INTRODUCTION
1. Sequential Optimization techniques.
2. Simultanuous Optimization techniques.
3. Combination of both.
1. Sequential Methods:
This method is alos referred to as the “Hill climbing method”. As first of all a small number
of experiments are done and further research will be done by using the increase or decrease
of response. In this way a maximum or minimum will be reached i.e. an optimum solution.
2. Simultanuous Methods:
This method involves the use of full  range of experiments by an experimental design and
the  results  are than used to  fit  in the mathematical  model.  And maximum or minimum
response will then be found through this fitted model.
Artificial   Neural Network (ANN) and Optimization of Pharmaceutical formulations:
ANN has been  entered in pharmaceutical studies to  forecast the relationship between the
response variables  and causal  factors. This  relationship is non-linear relationship. ANN is
most successfully used in Multi-objective simulatenous optimization problem.  (Takayama
K et  al.)  This problem  arises when the favorable conditions of formulation  for a single
property may not be favorable for other characteristics. 
                                    Radial basis functional network (RBFN) is proposed for multi-
objective   simultaneous  optimization problem (Anand P et al.). RBFN is an ANN in which
activation functions are radial basis functions (RBF). RBF is a function whose value depends
only on the distance from the center or origin.
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Applications:
  Through the optimization of the micro-encapsulation parameters such as shape of
microcapsules  ,the strength  of the micocapsule membranes  and  the  membrane
permeability of microcapsules now it is possible to develop more better forms of
microcapsules for the treatment of diabetes and liver diseases.
     Optimization  techniques are also  helpful  in  reducing the time of
experimentation,  study of  pharmacokinetic parameters  and  High  performance
liquid chromatographic analysis.
 One of the most important applications of  Pharmaceutical optimization is found in the
field of new   drug  discovery as the physicochemical and biological properties of a
system can be improved by chemical modifications using Optimization technique.
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Aim and objective
Fluconazole  is  triazole  antifungal  agent.  It  is  used  for  the  treatment  of  fungal
infections.Conventional preparations of fluconazole overdoses may cause hallucinations and
paranoid behaviour. Controlled release tablets will be a better alternation in reducing dose
and increasing efficacy with reducing fluctuations.
So our study was aimed to design and development and optimization of tablets containing
fluconazole as controlled release of drug for longer periods of time.By controlling the rate of
release  the over  dose  effects  such as  hallucinations  and paranoid  behaviour  will  also  be
minimized. So the objective was
 To prepare fluconazole tablet using different polymers for controlled release.
 Evaluate the effect of polymers and percentage drug release.
 To analyse the data statistically and optimize the formulation.
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PLAN OF WORK
1. Pre-formulation studies.
2. Preparation of tablets by direct compression method.
3. Evaluation of tablets for:
a. Hardness
b. thickness
c. Friability
d. Weight variation
e. Assay
f. InvitroDissolution studies.
g. Anti microbial studies
h. IR spectra studies
4. Kinetic models analysis
a. First order
b. Zero order
c. Higuchi model
d. Hixson-Crowell model
e. Korsmeyer- Peppas model.
                            5. Experimental Design
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Plan of Work
                            6.Statistical Analysis
                            7.Optimization
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Maderuelo.C et.al20 developed  model-independent approach  to optimize the release kinetics
of drugs from sustained-release formulations, using stavudine (d4T) as a model drug. This
approach  is  based  on  the  pharmacokinetic  simulation  of  drug  plasma  levels  through  a
semiparametric  approach  of  the  input  function  and  on  convolution  with  an  empirical
polyexponential  unit  impulse  response  function.  Input  functions  were  evaluated  using
different  zero-order  and  first-order  release  constants.  Optimum  drug  release  to  obtain  a
specific  pharmacokinetic  profile  was  approached  using  target  model-independent
pharmacokinetic parameters such as C(max)(SS), C(min)(SS), t(max)(SS), and peak-trough
fluctuations. A Monte Carlo simulation was performed to estimate the fractional attainment of
d4T plasma concentrations over therapeutic d4T levels. Zero-order (K(0) = 4 mg/h) and first-
order (K(1) = 0.05 h(-1)) release constants were optimal for the formulation of sustained-
release d4T tablets, plasma concentrations within the therapeutic range being achieved.
Prajapati .B.G et.al21  formulated and  evaluated   statical influence different concentration
of hydroxy propyl methyl cellulose K4M and ethyl cellulose on Propranolol hydrochloride
release compression coated tablet  using 32 full  factorial  design. Tablets were prepared by
direct  compression technique.  Time controlled  pulsatile  Propranolol  hydrochloride  tablets
containing  40  mg  of  Propranolol  hydrochloride  were  developed  using  different  ratio  of
hydroxypropyl  methylcellulose  and  ethyl  cellulose  that  retard  the  drug  release  in  the
physiological environment of stomach and 2-3 hr in intestine. Formulation was optimized on
basis  of  acceptable  tablet  properties  and  in  vitro drug  release.  To  analyse  the  release
mechanism of optimize batch zero order, first order, Higuchi, Hixson Crowell, Korsmeyer–
Peppas kinetic model were used. The kinetics release of optimize batch F3 was best explained
by zero order model, Hixson Crowell, and Korsmeyer–Peppas kinetic model.
MadgulkarARBhalekar et.al22  designed   sustained  release  matrix  tablets  of  venlafaxine
hydrochloride  using  ion  exchange  resin  with  the  incorporation  of  hydrophilic  and
hydrophobic polymer combinations. Venlafaxine HCl was loaded onto Indion 244 by batch
method  and  then  resinate  were  wet  granulated  with  ethyl  cellulose  and  blended  with
hydroxypropylmethylcellulose and compressed. A central composite design for 2 factors at 3
levels each was employed to systematically optimize drug release profile at 2 h and at 18 h.
Hydroxypropylmethylcellulose and ethylcellulose were taken as the independent variables.
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Response  surface  plots  and  contour  plots  were  drawn,  and  optimum  formulations  were
selected by feasibility and grid searches. Resinate shows inadequate sustained release profile.
Compressed matrices exhibited the anomalous release mechanism, as the value of release rate
exponent (n) varied between 08109 and 08719, resulting in regulated and complete release
until  20hrs.  Validation  of  optimization  study,  performed  using  five  confirmatory  runs,
indicated very high degree of prognostic ability of response surface methodology, with mean
percentage  error  as  1.152+/-1.88%.  Regulated  drug  release  study  indicates  that  the
hydrophilic  and  hydrophobic  matrix  tablets  of  venlafaxine  resinate  prepared  using
hydroxypropylmethylcellulose and ethylcellulose, can successfully be employed as a once-a-
day oral controlled release drug delivery.
Madgulkar.A et.al23 formulated buccal adhesive tablets of miconazole nitrate with prolonged
antifungal activity. The simplex centroid experimental design was used to arrive at optimum
ratio  of  carbopol  934P,hydroxypropylmethylcelluloseK4Mandpolyvinylpyrollidone,  which
will provide desired drug release and mucoadhesion. Swelling index, mucoadhesive strength
and  in  vitro drug  release  of  the  prepared  tablet  was  determined.  The  drug  release  and
bioadhesion was dependent on type and relative amounts of the polymers.  The optimized
combination  was  subjected  to  in  vitro antifungal  activity,  transmucosal  permeation,  drug
deposition in mucosa, residence time and bioadhesion studies. IR spectroscopy was used to
investigate  any interaction  between  drug  and  excipients.  Dissolution of  miconazole  from
tablets was sustained for 6 h.  based on the results  obtained, it  can be concluded that the
prepared  slow release  buccoadhesive  tablets  of  miconazole  would  markedly  prolong  the
duration  of  antifungal  activity.  Comparison  of  in  vitro antifungal  activity  of  tablet  with
marketed gel showed that drug concentrations above the minimum inhibitory concentration
were achieved immediately from both formulations but release from tablet was sustained up
to 6 h, while the gel showed initially fast drug release, which did not sustain later. Drug
permeation across buccal mucosa was minimum from the tablet as well as marketed gel; the
deposition  of  drug  in  mucosa  was  higher  in  case  of  tablet.  In  vitro residence  time  and
bioadhesive  strength  of  tablet  was  higher  than  gel.  Thus  the  buccoadhesive  tablet  of
miconazole nitrate  may offer  better  control  of  antifungal  activity as  compared to the gel
formulation.
Raghavendrarao N.G et.al24    formulated and evaluated   sustained release matrix tablets of
water soluble Tramadolhydrochloride using different polymers viz. Hydroxy propyl methyl
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cellulose (HPMC) and natural gums likeKaraya gum (KG) and Carrageenan (CG). Varying
ratios of drug and polymer like 1:1 and 1:2 were selected for thestudy. After fixing the ratio
of drug and polymer for control the release of drug up to desired time, the release rateswere
modulated by combination of two different rates controlling material and triple mixture of
three different ratecontrollingmaterial. After evaluation of physical properties of tablet, the in
vitro release study was performed in 0.1N HCl pH 1.2 for 2 hrs and in phosphate buffer pH
6.8 up to 12 hrs. The effect of polymer concentration andpolymer blend concentration were
studied. Different ratios like 80:20, 60:40, 50:50, 40:60 and 20:80 were taken.Dissolution
data was analyzed by Korsmeyer-Peppas  power law expression and modified power  law
expression. It was observed that matrix tablets contained polymer blend of HPMC/CG were
successfully  sustained  the  release  of  drug  upto  12  hrs.  Among  all  the  formulations,
formulation F16 which contains 20% HPMC K15M and 80% of CG,release the drug which
follow Zero  order  kinetics  via,  swelling,  diffusion and erosion and the release  profile  of
formulation  F16  was  comparable  with  the  marketed  product.  Stability  studies
(40±2ºC/75±5%RH) for 3 months indicated that Tramadol hydrochloride was stable in the
matrix  tablets.  The DSC and FTIR study revealed that  there was no chemical  interaction
between drug and excipients.
Bhalekar  MR  et.al25 prepared  a  sustained  release  drug  delivery  system  of  venlafaxine
hydrochloride by using a wax matrix system. The effects of bees wax and carnauba wax on
drug release profile was investigated. A 3(2) full factorial design was applied to systemically
optimize the drug release profile. Amounts of carnauba wax (X(1)) and bees wax (X(2)) were
selected as independent variables and release after 12 h and time required for 50% (t(50))
drug release were selected as dependent variables. A mathematical model was generated for
each response parameter. Both waxes retarded release after 12 h and increases the t(50) but
bees  wax  showed  significant  influence.  The  drug  release  pattern  for  all  the  formulation
combinations was found to be approaching Peppas kinetic model. Suitable combination of
two waxes provided fairly good regulated release profile. The response surfaces and contour
plots for each response parameter are presented for further interpretation of the results. The
optimum formulations were chosen and their predicted results found to be in close agreement
with experimental findings.
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Madgulkar A et.al26 formulated  and evaluated sustained release mucoadhesive tablets of
Itraconazole.  It  is  practically  insoluble  in  aqueous  fluids  hence  its  solid  dispersion  with
Eudragit E100 was prepared by spray drying. This was formulated in matrix of hydrophilic
mucoadhesive polymers Carbopol 934P (CP) and Methocel K4M (HPMC). The formulation
was  optimized  using  a  3(2)  factorial  design.  Amounts  of  CP and  HPMC were  taken  as
formulation variables for optimizing response variables i.e.  mucoadhesion and dissolution
parameters.  The  optimized  mucoadhesive  formulation  was  orally  administered  to  albino
rabbits, and blood samples collected were used to determine pharmacokinetic parameters.
The solid dispersion markedly enhanced the dissolution rate of itraconazole. The bioadhesive
strength of formulation was found to vary linearly with increasing amount of both polymers.
Formulations exhibited drug release fitting Peppas model with value of n ranging from 0.61
to 1.18. 
Mandal U et.al27 designed an oral sustained release matrix tablet of metformin HCl and to
optimize the drug release profile using response surface methodology. Tablets were prepared
by non-aqueous wet granulation method using HPMC K 15M as matrix forming polymer. A
central  composite  design  for  2  factors  at  3  levels  each  was  employed  to  systematically
optimize drug release profile. HPMC K 15M (X(1)) and PVP K 30 (X(2)) were taken as the
independent variables.  The dependent variables selected were % of drug released in 1 hr
(rel(1 hr)), % of drug released in 8 hrs (rel(8 hrs)) and time to 50% drug release (t(50%)).
Contour plots were drawn, and optimum formulations were selected by feasibility and grid
searches. The formulated tablets followed Higuchi drug release kinetics and diffusion was the
dominant mechanism of drug release, resulting in regulated and complete release within 8
hrs. The polymer (HPMC K 15M) and binder (PVP K 30) had significant effect on the drug
release from the tablets (p<0.05).  Polynomial mathematical  models, generated for various
response variables using multiple linear regression analysis, were found to be statistically
significant (p<0.05). Validation of optimization study, performed using 8 confirmatory runs,
indicated very high degree of prognostic ability of response surface methodology, with mean
percentage error (+/-S.D.) 0.0437+/-0.3285. Besides unraveling the effect of the 2 factors on
the in vitro drug release, the study helped in finding the optimum formulation with sustained
drug release.
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Sami Nazzal et.al28 described the objective of this study was to evaluate the effect of some
processing parameters on the release of lipid formulation from a tablet dosage form.A 17-run,
face-centered cubic design was employed to evaluate the effect of colloidal silicates (X1),
magnesium stearate mixing time (X2),  andcompression force (X3) on flow, hardness,  and
dissolution of Coenzyme Q10 (CoQ10) lipid formulation from a tablet  dosage form. The
optimized formulation was subsequently subjected to a short-term accelerated stability study.
All  preparations  had  a  flowability  index  values  ranging  from 77  to  90.  The  cumulative
percent of CoQ10  released within 8 h (Y5) ranged from 40.6% to 90% and was expressed by
the following polynomial equation: Y5 = 49.78 − 16.36X1 + 2.90X2 − 3.11X3 − 0.37X1X2 +
1.06X1X3  −  1.02X2X3  +  11.98X21+ 10.63X22− 7.10X23. When stored at 4  ◦C, dissolution
rates were retained for up to 3 months. Storage at higher temperatures, however, accelerated
lipid  release  and  caused  leakage,  and  loss  of  hardness.  Processing  parameters  have  a
profound effect on the release of lipid formulations from their solid carriers. While optimized
controlled release formulations could be attained, further considerations should be made to
prepare “liquisolids” that are physically stable at higher storage temperatures.
Huang  YB  et.al29  investigated   to  develop  propranolol  extended  releaseformulations
containing hydroxypropylmethylcellulose (HPMC). The results indicate that the drug release
from the tablet form containing a high amount of HPMC was incomplete, and avicel addition
could increase  the  release  percent  at  a  later  stage.  In  order  to  readily obtain  an  optimal
formulation, response surface methodology and multiple response  optimization utilizing a
quadratic polynomial equation was used. The model formulations were prepared according to
a factorial  design. The effects  of  causal  factors including the HPMC/drug ratio (X1) and
avicel level (X2), on drug release were also measured. The drug release percentage at 1.5, 4,
8, 14 and 24 h were the target response and were restricted to not more than 25%, 35-50%,
55-70%,  75-90%,  and  95-110%,  respectively.  The  results  showed  that  the  optimized
formulation provided a dissolution pattern equivalent to the predicted curve, which indicated
that  the optimal  formulation could  be obtained using response  surface methodology.  The
mechanism of drug release from HMPC matrices tablets followed quasi-Fickian diffusion.
 Philip Plumb.A et.al30  investigated  the effect of varying optimization parameters on the
proposed optimum of a tablet coatingformulation requiring minimization of crack velocity
and maximization of film opacity. An artificial neural network (ANN) comprising six input
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and two output nodes separated by a single hidden layer of five nodes was trained using 100
pseudo-randomly  distributedrecords  and  optimized  by  guided  evolutionary  simulated
annealing (GESA). GESA was unable to identify a formulation that satisfied both 21 a crack
velocity of 0 m s and a film opacity of 100% due to conflict centred on the response of the
properties to variation in pigmentparticle size. Constraining film thickness exacerbated the
property  conflict.  By  adjusting  property  weights  (i.e.  the  relative  importance  ofeach
property), GESA was able to propose formulations that were either crack resistant or that
were fully opaque. 
Kozo Takayamaet.al31  designed neural network based optimization of drug formulations. A
pharmaceutical formulation is composed of several formulation factors and process variables.
Several responses relatingto the effectiveness, usefulness, stability, as well as safety must be
optimized  simultaneously.  Consequently,  expertise  andexperience  are  required  to  design
acceptable pharmaceutical formulations. A response surface method (RSM) has widelybeen
used  for  selecting  acceptable  pharmaceutical  formulations.  However,  prediction  of
pharmaceutical responses based on  the second-order polynomial equation commonly used in
an RSM, is often limited to low levels, resulting in poor estimations of optimal formulations.
The purpose of this review is to describe the basic concept of the multi-objectivesimultaneous
optimization technique, in which an artificial neural network (ANN) is incorporated. ANNs
are being increasingly used in pharmaceutical research to predict the nonlinear relationship
between causal factors and responsevariables. Superior function of the ANN approach was
demonstrated by the optimization for typical numerical examples.
Svetlana Ibric et.al32 used generalized regression neural network (GRNN) in the design of
extended-releaseaspirin  tablets.  As model formulations,  10 kinds of  aspirin  matrix  tablets
were prepared. EudragitRS PO was used asmatrix substance. The amount of EudragitRS PO
and compression pressure were selected as causal factors. In-vitrodissolution–time profiles at
four different  sampling times,  as well  as coefficients  n  (release order)  and log  k  (release
constant)from the Peppas equation were estimated as release parameters.  A set  of release
parameters and causal factors were used astutorial data for the GRNN and analyzing using a
computer.  A GRNN  model  was  constructed.  The  optimized  GRNN  modelwas  used  for
prediction of formulation with desired in vitro drug release. For two tested formulations there
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was very goodagreement between the GRNN predicted and observed  in vitro profiles and
estimated coefficients. Calculated difference ( f) 1and similarity ( f ) factors indicate that there
is no difference between predicted and experimental observed drug release 2profiles. This
work illustrates the potential for an artificial neural network, GRNN, to assist in development
of extendedreleasedosage forms. 
HisakadzuSunada et.al33 prepared  and evaluated  rapidly disintegrating tablets   using both
direct compression and wet compression methods. Tablet properties, such as porosity, tensile
strength,  wetting  time  and  disintegration  time  were  evaluated,  and  the  formation  and
disintegration   mechanisms  of  the  tablets  were  elucidated.  Formulation  and  preparation
conditions were optimized using polynomial regression orartificial neural network .
 Paola Mura et.al34  applied statistical experimental design to evaluate the influence of some
process  and  formulation  variables  andpossible  interactions  among  such  variables,  on
didanosine release from directly-compressed matrix tablets based onblends of two insoluble
polymers, Eudragit RS-PM and Ethocel 100, with the final goal of drug release behavior
optimization. The considered responses were the percent of drug released at three determined
times, the dissolutionefficiency at 6 h and the time to dissolve 10% of drug. Four independent
variables were considered: tablet compression force, ratio between the polymers and their
particle size, and drug content. The preliminary screeningstep, carried out by means of a 12-
run  asymmetric  screening  matrix  according  to  a  D-optimal  design  strategy,  allowed
evaluation  of  the  effects  of  different  levels  of  each  variable.  The  drug  content  and  the
polymers ratio had the mostimportant effect on drug release, which, moreover, was favored
by greater  polymers  particle  size;  on  the  contrary  thecompression  force  did  not  have  a
significant effect. The Doehlert design was then applied for a response-surfacestudy, in order
to study in depth the effects of the most important variables. The desirability function was
used tosimultaneously optimize the five considered responses, each having a different target.
This procedure allowedselection, in the studied experimental domain, of the best formulation
conditions to optimize drug release rate.Theexperimental values obtained from the optimized
formulation highly agreed with the predicted values. The resultsdemonstrated the reliability
of the model in the preparation of extended-release matrix tablets with predictable drug
release profiles. 
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 Peter C.  Schmidt et.al35  prepared a rotatable central  composite  design  to  evaluate the
effects  of  lubricants  and  compression  force  on  the  physical  characteristics  ofeffervescent
tablets.  Effervescent  tablets  lubricated  with  a  combination  of  spray  dried  l-leucine  and
polyethylene glycol 6000 are preparedby direct compression and examined. Residual force,
crushing strength and disintegration time are considered as response variables andrelated to
the  l-leucine  and  polyethylene  glycol  concentrations  and  to  the  compression  force.  The
calculated  models  are  used  to  assess  theinfluence  of  the  production  factors  on  tablet
properties. As increasing amounts of l-leucine, showing good lubricating properties, reduce
thecrushing strength and prolong tablet disintegration, the l-leucine concentration is kept at a
low level. An optimum tablet formulationcontains 2% l-leucine and 3% polyethylene glycol
6000. The tablets have a tensile strength of 0.47 MPa and disintegrate in less than 2 min.
Predicted and experimental results are in agreement within a 95% CI.
Pao-Chu  Wuet.al36optimized   the  pH-dependent  release  of  nicardipine  hydrochloride
extended  release  formulationsby  using  simultaneously  combination  two  hydrophilic
polymers: hydroxypropylmethylcellulose (HPMC) and sodium alginate asretardant and avicel
as additive.  The constrained mixture experimental  design was used to prepare systematic
model  formulationswhich  were  composed  of  three  formulation  variables:  the  content  of
HPMC (X1), avicel (X2), and sodium alginate (X3). Theresponse surface methodology (RSM)
and multiple response optimization utilizing the polynomial equation were used to searchfor
the optimal formulation with specific release rate at different time intervals and to quantify
the effect of each formulationvariables. The drug release percent at 3, 6 and 12 h were the
target responses and were restricted to 10–30% (Y3 h), 40–65% (Y6 h) and not less than 80%
(Y12 h), respectively.The results showed that the effect of combination ofHPMCand sodium
alginatewasthemost influence factor on the drug release from extended-release matrix tablets.
The observed results of Y3 h, Y6 h and Y12 h coincided well with the predictions in the RSM
optimization  technique,indicating  it  was  quite  useful  for  optimizing
pharmaceuticalformulation.  The mechanism of  drug  release  from extended-release  matrix
tablets was dependent on the added amount of alginate.  The release kinetic of drug from
HPMC matrix tablets with alginate was followed the zero-order release pattern.
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 Khan M..A et.al37  aimed  (1) to evaluate the effect of formulation ingredients on the release
rate of Ubiquinone from its adsorbing solid compact; and (2) to prepare and evaluate an
optimized  self-nanoemulsifiedtabletformulation.  A three  factor,  three-level  Box–Behnken
design  was  used  for  the  optimization  procedure,  with  theamounts  of  copolyvidone  (X1),
maltodextrin (X2) and microcrystalline cellulose (X3) as the independent variables. The
response  variable  was  cumulative  percent  of  Ubiquinone  emulsified  in  45  min  with
constraints on weight, flowability index, tensile strength, friability and disintegration time of
the dry powdered  emulsion and the  resultant  compact.Based on the experimental  design,
different  Ubiquinone release rates and profiles were obtained. Mathematicalequations and
response  surface  plots were used to  relate  the dependent  and independent  variables.  The
regressionequation  generated  for  the  cumulative  percent  emulsified  in  45  min  was
Y6=64.10−12.32X1−4.36X2−25.53X3+6.99X1X2+3.97X1X3+9.70X2X3−8.98X1 2 −16.22X2
2 +17.10X3 2 . The optimization model predicted an 85.4% releasewithX1, X2 and X3 levels
of  66.6,  560.1 and100,  respectively.  A new formulation was  prepared according to  these
levels.  The observed responses  were in close agreement with the predicted values of the
optimized formulation.
 Sunil Jain et.al38  carried their work on formulation and process optimization to eliminate
pickingfrom  market  image tablets.  A tablet  formulation  when  compressed  using market
image tooling may cause picking of powder. A D-optimalstatistical experiment was designed
to  optimize  the  direct  compression  formulation  and  the  process  to  alleviate  picking  of
powder. The effects of levels of magnesium stearate, colloidal silicon dioxide (CSD), and
lubrication  time  onpicking  were  investigated  using  original  compression  tooling.  These
optimization results provided a small robust manufacturing region, hence a change in the cut
angles of embossed letters and numbers from 70° to 90° in themodified compression tooling
was evaluated. A statistical analysis of the data identified a robust manufacturingregion that
included formulations  containing magnesium stearate  1–1.25% w:w, CSD 0.1–0.3% w:w,
with alubrication time of 5–10 min when compressed using modified compression tooling.
The  results  indicate  a  significantreduction  in  picking  by  increasing  the  cut  angles  of
embossed letters and numbers in the modified compressiontooling. By evaluating interactions
between various variables, we demonstrate a concentration dependent effect of CSD on the
lubrication efficiency of magnesium stearate and compactability of microcrystalline cellulose
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containingformulation.  In  addition,  the  lubrication  efficiency  of  magnesium  stearate  is
maintained by blending CSD withpowder blend prior to lubrication with magnesium stearate.
Julijana Kristl et .al39  investigated  the development of the floating matrix tablets, which
after oral administrationare designed to prolong the gastric residence time, increase the drug
bioavailability  and  diminish  the  side  effects  ofirritating  drugs.  The  importance  of  the
composition optimisation, the technological process development for thepreparation of the
floating tablets with a high dose of freely soluble drug and characterisation of those tablets
(crushing force, floating properties in vitro and in vivo, drug release) was examined. Tablets
containing  hydroxypropylmethylcellulose  (HPMC),  drug  and  different  additives  were
compressed. The investigation shows that tabletcomposition and mechanical strength have
the greatest influence on the floating properties and drug release. With theincorporation of a
gas-generating  agent  together  with  microcrystalline  cellulose,  besides  optimum  floating
(floating lagtime, 30 s; duration of floating, \8 h), the drug content was also increased. The
drug release from those tablets wassufficiently sustained (more than 8 h) and non-Fickian
transport of the drug from tablets was confirmed. Radiologicalevidence suggests that, that the
formulated tablets did not adhere to the stomach mucus and that the mean gastric
residence time was prolonged (\4 h). 
 Campisi.B  et.al40  Stated that in pharmaceutical industries, the formulator is usually faced
with the optimisation of the excipient mixturecomposition aimed to prepare a product with
the  required  characteristics.  Experimental  research  methodologyrepresents  an  efficient
approach  for  solving  such  optimisation  problems.  Planning  mixture  experiments  using
specificdesigns allows to analyse the blending properties of each mixture component and
estimate an empirical modelapproximating the response of interest as a function of excipient
proportions. In this study the evolution of theophylline solubility in a four-component system
with  constraints  was  analysed  using  two  mixture  designapproaches:  a  classical  mixture
component  proportion  approach  and  a  mathematically independent  variable  approach. An
optimal region characterised by high solubility values was found and further  explored in
order to verifythe insensitivity of theophylline solubility to slight variations of the excipient
mixture composition.
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Adrian Bodea et.al41 optimized hydrophilic  matrix  tablets  using a  D-optimal  design.One
method of achieving sustained drug release is by the use of hydrophilic polymeric excipients
directly compressed with active ingredients into tablets. Hydrophilic polymers swell in the
presence  of  water  to  form  hydrogelstructures  from  which  drugs  are  released  by  slow
diffusion. The release rate modulation is obtained by the use ofdifferent types of polymer
alone or in combinations. Optimization of the release rate of propranolol hydrochloride from
mixturescontaining two hydrophilic polymers:  hydroxypropylmethylcellulose (HPMC) and
sodium carboxymethylcellulose(CMCNa) was made by mixture design. Mixing ratios of the
two polymers with the activeingredient were selected as formulation factors. Experimental
results were examined using a D-optimal quadraticmodel. Contour plots were formed based
on  the  model  to  assess  the  change  in  the  response  surface  in  order  tounderstand  the
relationship  between  dependent  and  independent  variables.  The  results  enabled  the
formulation  of  tablets  with  the  desired  dissolution  characteristics  together  with  a  fairly
completecharacterization of the system.Optimization of release rate was performed applying
constraints  on  the  cumulative  amounts  of  drug released  after  1,6  and  12  h  release  time
intervals.  Optimized formulations presented release rates  that  were  close to  the predicted
values.  Fitting the release data  from optimized formulations was performed according to
Korsmeyer  et  al.  (1983)  andPeppas  and  Sahlin  (1989)  kinetic  models.  Release  from
optimized formulations occurs mainly by Fickian diffusion butan important fraction of the
drug is released by polymer relaxation. 
Kozo Takayama  et.al42  develop a multi-objective simultaneous optimization technique in
which an artificial neuralnetwork (ANN) was incorporated. As model formulations, 18 kinds
of Trapidil tablet were prepared. The amounts ofmicrocrystalline cellulose, hydroxypropyl
methylcellulose  and  compression  pressure  were  selected  as  causal  factors.  In  orderto
characterize  the release  profiles  of  Trapidil,  the  release order  and  the rate  constant  were
estimated. A set of releaseparameters and causal factors was used as tutorial data for ANN
and  fed  into  a  computer.  Non-linear  relationships  betweencausal  factors  and  the  release
parameters were represented well with the response surface of ANN. The simultaneous
optimization of the sustained-release tablet containing Trapidil was performed by minimizing
the generalized distancebetween the predicted values of each response and the optimized one
that was obtained individually. The optimal formulations gave satisfactory release profiles,
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since  the  observed  results  coincided  well  with  the  predicted  results.  Thesefindings
demonstrate that a multi-objective optimization technique incorporating ANN is quite useful
in the optimization ofpharmaceutical formulations.
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                                   FLUCONAZOLE43
Structure  :
Chemical Formula  :  C13H12F2N6O
IUPAC Name          : 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
Weight                     : 306.2708
Description             : Fluconazole is a white crystalline solid which is slightly soluble in 
water and saline.
PHARMACOLOGY :
Mechanism of action :  Fluconazole interacts with 14-α demethylase, a cytochrome P-450 
enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component 
of the fungal cell membrane, inhibition of its synthesis results in increased cellular 
permeability causing leakage of cellular contents. Fluconazole may also inhibit endogenous 
respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to 
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mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid 
biosynthesis.
Pharmacodynamics  : Fluconazole, a synthetic antifungal agent of the imidazole class, is 
used to treat vaginal candidiasis. It inhibits the fungal lanosterol 14 alpha-demethylase which 
thereby prevents the formation of ergosterol which is an essential component in the fungal 
cell membrane.
Protein binding  : 11 to 12%
Metabolism        : Hepatic
Route of elimination  : In normal volunteers, fluconazole is cleared primarily by renal 
excretion, with approximately 80% of the administered dose appearing in the urine as 
unchanged drug.
Half life      : 30 hours (range 20-50 hours)
Clearance   : 0.23 mL/min/Kg [adults]
SIDE EFFECTS :
Nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools,
jaundice(yellowing of the skin or eyes),fever, chills, body aches, flu symptoms.
severe blistering, peeling, and red skin rash,easy bruising or bleeding, unusual weakness.
Toxicity    :Symptoms of overdose include hallucinations and paranoid behavior.
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                                 MALTODEXTRIN44
1. Structure                      :
 2. Chemical Name           :  Maltodextrin
3.Empirical Formula        :  (C6H10O5)n_H2O 
4. Molecular Weight         : 900–9000
5. Description                  :  Maltodextrin occurs as a nonsweet, odorless, white powder or
                                            granules. The solubility,hygroscopicity, sweet and compressibility
                                            of maltodextrin increase as the DE increases
6. Functional Category   :   Coating agent; tablet and capsule diluent; tablet binder; viscosity
                                            increasing agent.
7.Uses       :
 Use Concentration (%)
 Tablet binder (direct compression) 2–40
Tablet binder (wet granulation) 3–10.
8. Applications              :Maltodextrin is used in tablet formulations as a binder and diluent  in
                                        both direct-compression and wet-granulation or agglomeration
                                        processes. Maltodextrin is also widely used in confectionery and 
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                                       food products, as well as personal care applications. 
9. Incompatibilities       : Under certain pH and temperature conditions maltodextrin may
                                        undergo Maillard reactions with amino acids to produce
                                        yellowingor browning. Incompatible with strong oxidizing agents
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                      HYDROXY PROPYL METHYL CELLULOSE45
 1.Structure                         :
 2. Chemical Name            :  Cellulose hydroxypropyl methyl ether 
3. Molecular Weight         :  Molecular weight is approximately 10 000–1 500 000.
4. Description                    : Hypromellose is an odorless and tasteless, white or creamy-white
                                             fibrous or granular powder
5.Solubility                       :  Soluble in cold water, practically insoluble in hot water,
                                             chloroform, ethanol  (95%), and ether, but soluble in mixtures of 
                                             ethanol and dichloromethane, mixtures of methanol and 
                                             dichloromethane, and mixtures of water and alcohol.
6.Melting point                  :  190–2008C;  
7. Functional Category      :  Bioadhesive material; coating agent; controlled-release agent;
                                             dispersing agent;  release-modifying agent; solubilizing agent; 
                                              stabilizing agent; suspending agent; sustained-release agent; 
                                              tablet binder; thickening  agent; viscosity-increasing agent.
8. Applications         :          Hypromellose is widely used in oral, ophthalmic, nasal, and 
                                            Topicalpharmaceutical formulations. In oral products, 
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                                          hypromellose is primarily used as a  tablet  binder,in film-
                                          coating,( and as a matrix for use in extended release tablet
                                          formulations. 
9. Incompatibilities :   Hypromellose is incompatible with some oxidizing agents. Since it
                                     is  nonionic, hypromellose will not complex with metallic salts or 
                                    ionic  organics to form insoluble precipitates.
Dept of Pharmaceutics, KMCH College of Pharmacy, Coimbatore Page 
                                                                                         POLYMER PROFILE
                                       
                                 CARBOPOL-94046
Chemical Name        :   Polyacrylate – 1- cross polymer.
Empirical Formula  :   Carbomers are synthetic high-molecular-weight polymers of acrylic
acid  that are crosslinked with either allyl sucrose or allyl ethers   of  pentaerythritol.
Structural Formula : General Structure of Carbopol Polymers
Schematic drawing of a molecular segment of a cross-linked polyacrylic acid polymer
Description     :  Carbomers are white-colored, ‘fluffy’, acidic, hygroscopic powders with a
                          characteristic slight odor.
Solubility   :  Swellable in water and glycerin and, after neutralization, in ethanol (95%).   
Functional Category   :  Bioadhesive material; controlled-release agent; emulsifying agent; 
                                      emulsion stabilizer; rheology modifier; stabilizing agent; 
                                      suspending   agent; tablet binder.
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Applications in Pharmaceutical Formulation:
Use Concentration (%)
Emulsifying agent 0.1 – 0.5
Gelling agent 0.5 – 2.0
Suspending agent 0.5 – 1.0
Tablet binder 0.75 – 3.0
Controlled-release agent 5.0 – 30.0
                                        Table 1-Application of carbopol 940
Safety :
Carbomers are used extensively in nonparenteral products,particularly topical liquid
and semisolid preparations.  Gradespolymerized in  ethyl  acetate  may also be used in oral
formulations. There is no evidence of systemic absorption ofcarbomer polymers following
oral administration.
                                         
                  
                                ETHYL CELLULOSE47
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1.structure  :
2. Chemical Name            : Cellulose ethyl ether 
3. Empirical Formula        :  C12H23O6(C12H22O5)
4. Description                   :  Ethylcellulose is a tasteless, free-flowing, white to light 
                                             tan-colored powder.
5.Solubility                        :  Ethylcellulose is practically insoluble in glycerin,
                                              propylene glycol, and water
6. Functional Category     :  Coating agent; flavoring agent; tablet binder;
                                             tablet filler;  viscosityincreasing agent.
E
7.uses                                  :  Use Concentration (%)
                                              Sustained-release tablet coating 3.0–20.0
8 Applications      :  Ethylcellulose is widely used in oral and topical
                                pharmaceutical formulations.The main use of ethylcellulose in oral
                                formulations is as a hydrophobic coating agent for tablets and granules.
                                Ethylcellulose is additionally used in cosmetics and food products.
9. Incompatibilities :
                                   Incompatible with paraffin wax and microcrystalline wax.
                                       
                                             LACTOSE48
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1. structure                        :
2. Chemical Name            :  O-b-D-Galactopyranosyl-(14)-b-D-glucopyranose
3. Empirical Formula        : C12H22O11
4. Molecular Weight         :     342.30
5. Description      : Anhydrous lactose occurs as white to off-white 
                              crystalline particles or powder. Several different brands of 
                              anhydrous  lactose are commercially available which contain anhydrous
                              b- lactose and anhydrous a-lactose. Anhydrous lactose typically 
                             contains  70–80% anhydrous b-lactose and 20–30% anhydrous a-lactose.
6.Solubility            :   Soluble in water; sparingly soluble in ethanol (95%)and ether.
7. Functional Category    :   Directly compressible tablet excipient; dry powder inhaler 
                                             carrier; lyophilization aid; tablet and capsule diluent; tablet and
                                            capsule filler.
8. Applications   :                Anhydrous lactose is widely used in direct compression tableting
                                            applications, and as a tablet and capsule filler and binder.
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                                            Anhydrous lactose can be used with moisture-sensitive drugs due
                                            to its low moisture content. It may also be used in
                                            intravenous   injections.
9. Incompatibilities     :     Lactose anhydrous is incompatible with strong oxidizers. 
   
                                                        
                                               STARCH49
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1. Structure                       :
2. Chemical Name            :   Starch 
3. Empirical Formula         :   (C6H10O5)     
4.Molecular Weight           :   300–1000.
5. Description                    :   Starch occurs as an odorless and tasteless, fine, white to
                                              off- white  powder. It consists of very small spherical or
                                              ovoid   granules or  grains whose  size and   shape 
                                              are  characteristic for each botanical  variety.
6. Solubility                       :   Practically insoluble in cold ethanol (96%) and in cold Water.
7. Functional Category     :  Tablet and capsule diluent; tablet and capsule disintegrant; tablet
                                              binder; thickening agent.
S8. Applications               : Starch is a versatile excipient used primarily in oral solid-      
                                            dosage formulations where it is utilized as a binder, diluent,and 
                                            disintegrant.Specific starch varieties with a high amylose content 
                                            (resistant starches) are used as insoluble fiber in clinical nutrition,
                                            and also for colon-targeting applications.
9. Incompatibilities   :      Starch is incompatible with strongly oxidizing substances. 
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                                         Colored  inclusion compounds are formed with iodine.
      
                                      
                                            TALC50
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1.  Chemical Name                :  Talc
2. Empirical Formula             :  Mg6(Si2O5)4(OH)4. 
3. Description             :   Talc is a very fine, white to grayish-white, odorless,      
                                        impalpable, unctuous, crystalline powder. It adheres readily to
                                        the skin and is soft to the touch and free from grittiness.
4.Solubility              :    Practically insoluble in dilute acids and alkalis, organic solvents, 
                                     and  water.
5. Functional Category           :  Anticaking agent; glidant; tablet and capsule diluent,
                                                    tablet and capsule lubricant.
6. Applications             :    Talc was once widely used in oral solid dosage formulations
                                          as a lubricant and diluent. However, it is widely used as a
                                          dissolutionretardant in the development of controlled-release
                                          products.Talc is also used as a lubricant in tablet formulations.
7. Incompatibilities     :  Incompatible with quaternary ammonium compounds.
                       
                                    
              
                                  MAGNESIUM STEARATE51
1.structure                        :
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2. Chemical Name           :  Octadecanoic acid magnesium salt.
3. Empirical Formula        : C36H70MgO4    
4.Molecular Weight          :  591.24
5 Structural Formula        : [CH3(CH2)16COO]2Mg
6. Description                   : Magnesium stearate is a very fine, light white, precipitated
                                           or  milled, impalpable powder of low bulk density, having a
                                           faint odour of stearic acid and a characteristic taste. The powder
                                           is greasy to thetouch and readily adheres to the skin.
7.Functional Category      : Tablet and capsule lubricant.
8. Applications                  :  Magnesium stearate is widely used in cosmetics, foods,
                                             And  pharmaceuticalformulations. It is primarily used as
                                             a lubricant in capsule and tablet manufacture at concentrations  
                                             between 0.2 and 5.0% w/w. It is also used in barrier creams. 
9. Incompatibilities         :   Incompatible with strong acids, alkalis, and iron salts
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            Table-2: Instruments used
INSTRUMENTS SUPPLIER/ MANUFACTURER
Single pan analytical balance Shimadzu corporation Ltd - Japan
    Tablet punching machine
(Rimek  –  MINI  PRESS  –  II  MT),
Karnavati engineering Ltd - Gujarat
 Pfizer hardness tester
Shreeji  scientific  &  laboratory
instruments Ltd - Mumbai
Roche  friabilator
(Thermonik  C-FTA20),  Campbell
electronics Ltd –Mumbai
Tap density apparatus
(Thermonik  C-TDA2),  Campbell
electronics Ltd –Mumbai
Vernier calliper Electro labs Ltd - Mumbai
Dissolution apparatus
(Thermonik  DRS-8),  Campbell
electronics  Ltd –Mumbai
Stability chamber Technico Ltd - Mumbai
UV spectrophotometer Shimadzu corporation Ltd - Japan
            Table-3: Materials used
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MATERIAL SUPPLIER/ MANUFACTURER
Fluconazole    (gift sample) Aurobindo labs.ltd-Hyderabad
Carbopol-940 Otto kemi.ltd - Mumbai
HPMC Lobachemie.ltd - Mumbai
Ethyl cellulose SD fine chemicals.ltd - Mumbai
Maltodextrin Mylan laboratories.ltd-Hyderabad
Starch SD fine chemicals.ltd - Mumbai
Lactose monohydrate SD fine chemicals.ltd - Mumbai
Talc SD fine chemicals.ltd - Mumbai
Magnesium stearate Lobachemie.ltd - Mumbai
MATERIALS AND METHODS
METHODOLOGY:
A. Determination of λ max:
Absorption spectra of Fluconazole:
a)   A stock solution of 1mg/ml of Fluconazole was prepared by dissolving 100 mg of drug
in small quantity of  buffer of PH 6.8 and sonicated for five min and diluted with buffer of
PH 6.8.
b) The stock solution was serially diluted to get solutions in the range of 2-10 µg/ml and λ
max of the solution was found out from 200 - 400 nm.
c)  The λ max of the solution was found to be 260 nm. 
B.  Determination of Standard Curve:
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a) A stock solution of 1mg/ml of Fluconazole was prepared by dissolving 100 mg of drug in
small quantity of distilled water and sonicated for five min and diluted with 100 ml of
distilled water.
b) The stock solution was serially diluted to get solutions in the range of 2-10 µg/ml and
 λmax of the solution was found out.
c) The  absorbance  of  the  different  diluted  solutions  was  measured  in  a  UV
spectrophotometer at 260 nm.
d) A calibration curve was plotted by taking Concentration of the solution in  g on X-axis
and absorbance on Y-axis and Correlation Coefficient “r” was calculated.
PREPARATION OF POWDER BLEND:
The  ingredients  were  accurately weighed  and  sifted  through sieve  #60,  and  then  the
materials except talc and magnesium stearate were blended using mortar and pestle for 10 min in
an ascending order. Powder mixture then lubricated with talc and magnesium stearate for 5 min.
Formulation of controlled release Tablets: 
Controlled  release  tablets  were  formulated  by  direct  compression  technique.  In  direct
compression  method  Fluconazole  and  respective  polymer  of  each  formulation  were  mixed
separately in a mortar. Each batch of tablets is  prepared using two various polymers as four
formulations in the ratios 1:1, 1:2, 2:1,2:2 . The lubricant was added to the powder mixture and
mixed for  another  2-3 min by hand. The powder mixture was directly compressed in single
station tablet punching machine using talc and Magnesium stearate as a lubricant. The punched
tablet weight about 200 mg (±25mg) and measured 4 mm in diameter punch.
Table-4 : Formulation Scheme  of Fluconazole Controlled Release tablets(each ingredients 
in  mg)
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Formul
ation   
code  
 
Fluconazole
Maltodex
trin
HPMC Carbopol 
940
Ethyl
Cellu
lose
Star
ch
Lactose Talc Magnes
ium 
stereate
Total 
weight  
(mg)
MH1      100 20 20 - - 28        28 2 2 200
MH2      100 20 40 - - 16 16 2 2 200
MH3      100 40 20 - - 16 16      2      2 200
MH4      100 40 40 - - 8 8      2      2 200
CH1      100 - 20 20 - 28 28      2      2 200
CH2      100 - 40 20 - 16 16      2      2 200
CH3      100 - 20 40 - 16 16      2      2     200
CH4      100 - 40 40 - 8 8      2      2     200
CE1      100 - - 20 20 28 28      2      2    200
CE2      100 - - 20 40 16 16      2      2    200
CE3      100 - - 40 20 16 16      2      2    200
CE4      100 - - 40 40 8 8      2      2    200
HE1      100 - 20 - 20 28 28      2      2    200
HE2      100 - 20 - 40 16 16      2      2   200
HE3      100 - 40 - 20 16 16      2      2    200
HE4      100 - 40 - 40 8 8      2      2    200
EVALUATION OF POWDER BLEND:
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The prepared powder blends were subjected to evaluation as per the methods suggested
in the Indian Pharmacopoeia52 like Angle of repose, Bulk density, Tap density, Compressibility
index &Hausner’s ratio.
DRUG-EXCIPIENT COMPATABILITY STUDY BY FTIR:
IR spectra matching approach was used for detection of any possible chemical interaction
between drug and polymers. A physical mixture (1:1) of drug and polymer was prepared and
mixed  with  suitable  quantity  of  potassium  bromide.  About  100mg  of  this  mixture  was
compressed to form a transparent pellet using a hydraulic press at 6 tons pressure. It was then
scanned from 4000 to 400 cm-1  in FTIR spectrometer. The IR spectrum of the physical mixture
was  compared  with  those  of  pure  drug  and  polymers;  matching  was  done  to  detect  any
appearance or disappearance of peaks.
Angle of repose:     
The angle of  repose  is  the maximum angle formed between  the  surface of  a  pile  of
powder  and  horizontal  surface.  It  is  determined  by  the  funnel  method.  A funnel  was  kept
vertically at a specified height and the funnel bottom was closed. 10 gm of sample powder was
filled inside the funnel. Then funnel was opened to release the powder to form a smooth conical
heap which just touches the tip of the funnel. From the powder cone, the radius of the heap (r)
and the height of the heap (h) were measured. The angle of repose is represented as ‘θ’ and
calculated using the following equation:
                        Tan θ = h/r                                          
Table-5: Flow properties and corresponding Angles of repose
FLOW PROPERTY ANGLE OF REPOSE (DEGREES)
Excellent 25-30
Good 31-35
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Fair 36-40
Passable 41-45
Poor 46-55
Very poor 56-65
Very, very poor >66
Bulk Density:
The bulk densities of the powder blends were determined by transferring an accurately
weighed 10 gm of sample powder to the graduated 50 ml measuring cylinder. The initial volume
(bulk volume) was noted. The bulk density calculated using formula:
Bulk Density = Weight of Sample / Bulk Volume                  
Tapped Density: 
An accurately weighed 10 gm of sample powder was transferred to the graduated 50ml
measuring cylinder and placed on the tap density test apparatus. The apparatus was operated for
a fixed number of taps (500 taps). The final volume (tapped volume) of the powder mass was
noted. The tapped density calculated using formula:
Tapped Density = Weight of Sample/ Tapped Volume              
Compressibility Index:
The compressibility index  is  determined  from the  bulk  volume  and  tapped
volume  of  the  powder.  The  basic  method  used  for  the  determination  of
compressibility index is  to measure the bulk volume and the final  tapped volume
after tapping until no change in volume occurs. It  is represented in percentage.
% Compressibility = (Tapped density - Bulk density) / Tapped density X 100         
         Table-6: Scale of Flowability based on Compressibility Index
COMPRESSIBILITY
INDEX (%)
FLOW
CHARACTER
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≤10 Excellent
11-15 Good
16-20 Fair
21-25 Passable
26-31 Poor
32-37 Very poor
>38 Very, very poor
Hausner’s Ratio: 
Hausner’s ratio is the ratio of bulk density to the tapped density of powder (or) initial
volume of the powder mass to the final volume of the powder mass obtained after specified
number of tapping.
                              Table-7: Scale of Flowability based onHausner’s Ratio
EVALUATION OF
CONTROLLED RELEASE TABLET:
Weight variation test:
20 tablets were selected randomly and weighed. Average weight was calculated. Each
tablet was weighed individually. Weight of the individual tablets was compared with the average
weight and reported with standard deviation.  Since the tablets weighed more 200mg,  Indian
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HAUSNER’S RATIO FLOW CHARACTER
1-1.11 Excellent
1.12-1.18 Good
1.19-1.25 Fair
1.26-1.34 Passable
1.35-1.45 Poor
1.46-1.59 Very poor
>1.60 Very, very poor
Materials and methods
Pharmacopoeia specifies that  the tablets pass the test  if not  more than two of the individual
weights deviate from the average weight by more than 7.5%.
              Table-8:Weightvariation limit as per Indian Pharmacopoeia
Percentage deviation allowed under weight variation test
Average weight of tablet Percentage deviation
≤ 80mg 10%
80-250mg 7.5%
≥ 250mg 5%
Thickness and diameter: 
Thickness is measured during tablet compression using Verniercalliper.
Hardness:
Hardness of the tablets were measured using Pfizer tablet hardness tester. A sample of 5
tablets were randomly taken from each batch and were held vertically in between the jaws
which were pressed with hand until the tablet broken. The reading was noted from the needle of
pressure dial which may be expressed in kilograms.
Friability:
Friability is performed to evaluate the ability of tablet to withstand abrasions. Ten tablets
were weighed and placed in the tumbling chamber which was rotated for 100 revolutions. The
tablets were dedusted and again weighed. The loss in weight indicated the friability.
           A-B                                     
    % Friability =                  ×100
 B       
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Where A=Initial weight of tablet
B=Weight of tablet after 100 revolutions.
Assay of tablet :53
Weigh 20 tablets  and powder them.  Take powdered tablet  equivalent  to 0.011gm i.e.  about
0.16gm in 100ml of beaker which is previously dried. Add 50ml of chloroform in it. Keep it on
ultrasonic bath for 15-20 min with slight heating then filter the chloroform in another dry beaker
and evaporate chloroform to dryness. After evaporation make dilution with distilled warer to
10ml by rinsing the beaker. The absorbance of the diluted solution was then measured at 260nm
using distille wateras the blank solution. The assay value is calculated by using the formula:
Assay =     
Test reading
Standard reading      ×    
Wieght of standard
Weight of test    × 100
In vitro Dissolution studies:
The  drug  release  from  different  formulations  were  determined  using  a  USP  XIX  Paddle
apparatus under sink condition.The dissolution medium was 900 ml buffer 0.1NHCL for 2 hours
followed by  buffer of PH 6.8 at 37± 0.20 C,up to 8hrs of the study, paddle speed of 50 rpm
,sample(5ml) was withdrawn at predetermined time intervals,and replaced by an equal volume of
dissolution  medium.Drug  content  in  the  dissolution  sample  was  determined  by  UV
spectrophotometer at 260nm.
            In vitro Dissolution studies: Parameters
       Instruments                  : USP XIX Dissolution rate test apparatus
       Type                             :  Paddle
       Medium                        :  900 ml 
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       Temperature                 : 37± 0.20c.
       RPM                             :  50
       Duration                        :  8hr
      Sampling time                : 1 hr
     Amount withdrawn       :  5ml
                        λmax            :  260nm
ANTIMICROBIAL STUDIES54
In microbial assay response of a growing populations of microorganisms in the antimicrobial
environment is measured.The usual method involves agar diffusion assays  in which the drug
diffusion to agar seeded with a suseptible microbial population produce a zone of inhibition of
growth in the commonest for samles to be assayed or applied in same form of reservoir to this
layer  agar  sealed  with  indication  organisms.The  drug  diffusion  in  to  the  medium and  after
incubation zone of growth inhibition forms.
In this antibiotic standard at different cocentration are incorporated in to liquid media to extend
the growth inhibition of test organism is measured using turbidometrically using a saphalometer.
The  diameter  of  this  test  or  unknown   reflects  the  concentration  of  the  compound  being
assayed,and it  is compared with similar zones produced by various known concentrations of
standard or reference compound.
In  this  technique  assay the agar  medium in a  petridish is  inoculated with  the test  organism
(mesonidinium rubrum). The drug diffuses through agar anda zone of inhibition produced is
measured.
ASSAY 
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Diffusional assays are carried out on a solid medium, usually an agar medium, which is suitable
for growth of the test organism.The compound to be assayed is allowed to diffuse through the
medium in a radial fashon from a pad or cup so that the adjacent growth of the test organism is
either stimulated,  as  with growth factor  .In  this experiment test  organism used for  testing is
mosonodinium rubrum a fungus.  
The diameter of this area reflects the concentration of the compound being assayed,and it  is
compared with similar zones produced by various known concentrations of standard or reference
compound.The diameter  of  the standard  are  plotted against  logarithms  of  the  concentrations
used,and the linear portion of this standard curve is used for determining the actual concentration
of the sample being assayed.
There  are  two  types  of  diffusion  assay  and,  although  somewhat  similar,  each  has  its  own
particular advantages.
1.Cylinder Method
2. Paper Disc Method
DRUG RELEASE KINETICS55-57:
To study the release kinetics, data obtained from in-vitro drug release studies were plotted
in various kinetic models: zero order (Equation 6) as cumulative amount of drug released vs.
time,  first  order  (Equation 7)  as  log cumulative percentage of  drug remaining vs.  time,  and
Higuchi’s model (Equation 8) as cumulative percentage of drug released vs. square root of time.
C = K0 t 
Where,
K0:is the zero-order rate constant expressed in units of concentration/time 
t: is the time in hours. 
A graph of concentration vs. time would yield a straight line with a slope equal to K0
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and intercept the origin of the axes.
LogC = LogCo– kt/2.303 
Where,
C0:is the initial concentration of drug, 
K: is the first order constant, and t is the time.
Q = Kt1/2
Where,
K: is the constant reflecting the design variables of the system 
t: is the time in hours. Hence, drug release rate is proportional to the reciprocal of the
square root of time.
To evaluate the drug release with changes in the surface area and the diameter of
the particles/tablets, the data were also plotted using the Hixson-Crowell cube root 
law (Equation 9):
0 t3 Q -3 Q =kHC-t
 
Where,
Qt is the amount of drug released in time t, 
Q0 is the initial amount of the drug in the tablet, and
KHC is the rate constant for the Hixson-Crowell rate equation, as the cube root of the
percentage of drug remaining in the matrix vs. time.
Mechanism of Drug Release58:
To evaluate  the  mechanism of  drug release  from Propranolol  Hydrochloride  floating
matrix tablet, data of drug release were plotted in Korsmeyeretal’sequation (Equation 10) as log
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cumulative percentage of drug released vs. log time, and the exponent n was calculated through
the slope of the straight line.
Mt-M∞ = Ktn  
Where,
Mt/M∞is the fractional solute release, 
t is the release time, 
K is a kinetic constant characteristic of the drug/ polymer system, and 
n is an exponent that characterizes the mechanism of release of tracers. 
Exponent n values drug release mechanism
    0.45 0.43  Fickian diffusion
    0.45< n <0.89 0.43< n <0.85 Anomalous transport
     0.89 0.85 Case II transport.
                        
EXPERIMENTAL DESIGN59 :
Factorial  design is an experimental  design technique, by which the factor involved and their
relative importance can be assessed. In the present study, the formulations, which are designed
based  on  22  full  factorial  design  containing  2  factors  evaluated  at  two  levels  and  the
experimental trials were performed at all possible combinations. Hardness, time to release 1st
hour, time(in hrs ) taken to release T50%,zone of inhibition were taken as dependent variables
and values were fitted to SPSS statistics 17.0.
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• The  22  full  factorial  design  was  considered  and  according  to  the  model  totally  16
experiments were conducted,from which  four selected formulations were choosen for the
study of optimization.
• Experiment designed by 22 factorial design,producing 4 factorial points.This design  
generally involves dependent variables Y,independent variable X.Two independent 
variable selected for this study were X1,amount of maltodextrin,X2,amount of Carbopol 
940, X3,amount of HPMC , X4,amount of ethyl cellulose.The dependent variable were 
Y1,amount of drug release at 8th hour;Y2,Zone of inhibition.
The two  formulation variables evaluated include: 
Factor A:Independent variables X1-X4 taken based on different ratios of polymers in milligrams
(Matlodextrin:HPMC,Carbopol  940:HPMC,  Carbopol940  :Ethyl  Cellulose,  HPMC:Ethyl
Cellulose in the ratios 1:1,1:2,2:1,2:2) 
Factor  B:   Dependent  variables  Y1,Y2  taken  based  on  amount  of  drug  released  at  8th
hour(Y1),Zone of Inhibition(Y2).
Statistical Analysis :
The  effect  of  formulation  variable  on  the  response  variable  was  statistically  evaluated  by
applying ANOVA.The design was evaluated by quadratic model.
Y=b0+b1X1+b2X2 + b3X3+ b11X12+b22X22 +B33X32 +b12X1X2+  B13X1X3
     +b23X2X3
Where  Y is  the  response  variable,  bo  is  the  constant  and  b1,b2,b3...etc  are  the  regression
coefficients of  formulation variable.X1,X2 and X3 stand for main effect;X1X3,X2X3and X1X2
are interaction term.X12,X22 and X32 are quadratuc terms of the independent variable to evaluate
nonlinearity.
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Optimization60  :
The final optimized formula was found after analyzing the response variable Y1 and Y2.The
ANOVA study of  each  response  variable  yielded  the  best  fitting  polynomial  model  for  that
variable.The target of percentage release and zone of inhibition set at minimum and given equal
weightage to both responses for optimization.By numerical optimization theoritically optimized
formula with its percentage release and zone of inhibition were found out and compared with
obtained in the experiments.
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                                  RESULTS & DISCUSSION
1.Determination of λmax of of fluconazole
Fluconazole showed absorbance maxima at 260nm.
2.Calibration curve of Fluconazole
Calibration curve of fluconazole were plotted by measuring the absorbance of standard drug 
solution containing 1 to 10 µg/ml  by UV spectrophotometer at 260nm.Calibration curve 
shows good linearity with  R2 value 0.996 using 0.1N HCL,R2 value0.999 using buffer of PH 
6.8.
Table-9:Calibration curve Data of Fluconazole in 0.1N HCL at 260nm:
Fig.4: Calibration curve of Fluconazole in 0.1N HCL at 260nm
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Concentration (µg/ml) Absorbance at 260 nm
0 0
2 0.0525
4 0.0986
6 0.1625
8 0.2164
10 0.2817
                                                                            RESULTS AND DISCUSSION
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Table 10 :Caliberation Curve data of Fluconazole in buffer PH 6.8 :
Concentration(µg) Absorbance 
(260nm)
0 0
2 0.046
4 0.084
6 0.128
8 0.172
10 0.211
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Fig.5 :Calibration curve of Fluconazole in buffer PH6.8 at 260nm
      3. IR SPECTRA:
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Table 11 : Interpretation of studied FTIR peaks with their characteristics 
functional groups
S.N
o
Peaks Characteristic functional group
1 2926-2853           CH2 CH Stretching
2 1140           C-O Stretching of Alcohol
3 1419-1342           OH Bending vibration
4 1504           C=N Stretching
5 1079           C-F Stretching
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By Interpretation of FTIR peaks with their characteristics functional groups, it was observed 
that there was no  interactions between drug and excipients  for the formulations  since there 
was  no much deviation in peaks obtained for formulations (MH4,CH4,CE4,HE4)  when 
compared with the Fluconazole drug standard.
Dept of Pharmaceutics, KMCH College of Pharmacy, Coimbatore Page 68
                                                                            RESULTS AND DISCUSSION
4.Preformulation Studies:
 controlled release layer blend showed angle of repose between 26.240 to 29.620,bulk density 
between 0.3892 gm/ml to 0.4426 gm/ml,tapped density between 0.3806  gm/ml to 0.4167 
gm/ml ,hausner ratio between 1.05 to 1.15 ,compressibility index between 8.09 to 12.08,these
results are presented in the table no12.
PRE-COMPRESSION EVALUATION:
Table-12:Pre-compression parameters of powder blend
Formulation 
code
Angle of 
repose 
(Degrees)
Bulk 
density 
(gm/cm³)
Tapped 
density 
(gm/cm³)
Compressibility 
index (%)
Hausner’s 
ratio
MH1 28.32 0.4180 0.3842 8.09 1.1
MH2 26.24 0.4001 0.4024 8.92 1.1
MH3 28.14 0.4426 0.4140 9.02 1.08
MH4 26.31 0.4000 0.3922 7.09 1.1
CH1 28.42 0.4202 0.4021 5.28 1.15
CH2 29.22 0.4062 0.4426           12.04 1.1
CH3 29.62 0.3930 0.3968 11.06 1.1
CH4       27.68 0.4195 0.3806 5.14 1.12
CE1 28.52 0.4195 0.4165 4.78 1.12
CE2 28.62 0.4126 0.3824 9.06 1.14
CE3 29.39 0.3996 0.3964 12.08 1.15
CE4 27.94 0.3982 0.3825 10.02 1.15
HE1 27.54 0.4062 0.4028 9.09 1.05
HE2 28.96 0.3892 0.3872 4.07 1.14
HE3 28.81 0.4324 0.4320 6.28 1.14
HE4 27.68    0.4124 0.4108 8.65 1.1
  5. POST-COMPRESSION EVALUATION OF TABLETS:
   Evaluation of physical parameters:
     Table-13:Physical parameters of prepared tablets
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Formulatio
n code 
Weight 
variation
(mg), 
n=20
Hardness 
(Kg/cm²), 
n=5
Thicknes
s (mm), 
n=3
Friabilit
y (%) 
Assay   
(%Drug 
content), 
n=3 
MH1 0.94 5.1 3.2 0.52 91.32
MH2 0.98 4.9 3.1 0.46 93.25
MH3 0.96 5.1 3.1 0.61 92.54
MH4 0.88 5.2 3.2 0.72 94.62
CH1 0.89 5.4 3.1 0.56 92.51
CH2 0.94 5.2 3.2 0.68 93.12
CH3 0.92 4.8 3.4 0.62 93.62
CH4 0.94 5.5 3.2 0.68 95.74
CE1 0.88 4.8 3.1 0.51 92.47
CE2 0.87 5.2 3.2 0.48 91.32
CE3 0.88 5.4 3.3 0.61 94.12
CE4 0.88 5.3 3.2 0.56 94.68
HE1 0.96 4.8 3.1 0.71 93.53
HE2 0.98 5.2 3.2 0.58 90.25
HE3 0.92 5.1 3.2 0.65 94.68
HE4 0.86 5.3 3.4 0.68 94.82
Physical properties of the tablet for all formulation were evaluated and data given in table no 
12,    Fromweight variation test it is observed that  weight of all formulations varies between 
0.87 to 0.98% , Hardness of the tablet  was evaluated by using pfizer hardness tester ,result 
showed in the range of 4.8 to 5.4 kg/cm2, thickness of the tablet were foundeinbetween 
3.1mm to 3.4mm.Friability result gave percentage loss ranging from 0.46 % to 0.72 % for all 
the formulation which is with in prescribed limit (± 1%).
6.Invitro Drug Release Profile :
  Table-14  : Results of in-vitro drug release study of Maltodextrin-HPMC
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Fig.11:Dissolution Profiles of Formulations MH1-MH4
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  Table-15 : Results of in-vitro drug release study of Carbopol 940-HPMC
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Time(hrs) MH1 MH2 MH3 MH4
0 0 0 0 0
1 11.27 7.171 8.859 12.27
2 22.96 15.6 15.18 16.45
3 29.73 21.93 24.04 23.2
4 37.12 32.06 32.06 29.53
5 46.26 38.81 44.71 37.12
6 54.96 43.03 56.53 44.71
7 65.54 54.42 62.43 53.78
8 74.56 67.52 71.61 62.37
                                                                            RESULTS AND DISCUSSION
Time(hrs) CH1 CH2 CH3 CH4
0 0 0 0 0
1 9.703 8.85 8.92 6.35
2 15.58 15.18 15.42 10.91
3 24.46 21.93 24.21 14.28
4 35.43 30.79 31.32 20.94
5 46.4 38.81 37.18 27.42
6 55.68 46.82 42.18 36.46
7 63.39 52.31 50.62 45.52
8 71.74 61.59 58.73 52.32
 Fig.12:Dissolution Profiles of Formulations CH1-CH4
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Table-16: Results of in-vitro drug release study of Carbopol 940-Ethyl Cellulose
Time(hrs) CE1 CE2 CE3 CE4
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0 0 0 0 0
1 8.859 8.85 7.171 6.75
2 15.18 15.18 13.07 11.81
3 24.04 21.93 20.5 17.29
4 32.06 30.79 27.5 21.93
5 44.71 38.81 35.85 28.68
6 56.53 46.82 44.32 37.43
7 62.43 52.31 53.64 46.92
8 71.64 61.59 59.25 55.84
Fig.13:Dissolution Profiles of Formulations CE1-CE4
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 Table-17: Results
of in-vitro drug 
release study of  
HPMC-Ethyl 
CelluloseXTime(h
rs)
HE1 HE2 HE3      HE4
0 0 0 0 0
1 8.859 8.24 9.281 8.22
2 16.03 15.71 15.6 14.76
3 24.46 23.28 26.57 21.09
4 36.28 29.42 35.85 28.84
5 46.82 35.56 39.65 36.45
6 53.15 43.12 43.45 43.03
7 62.43 53.22 54.37 48.51
8 71.71 66.54 65.52 54.15
                                                                            RESULTS AND DISCUSSION
Fig.14 :Dissolution Profiles of Formulations HE1-HE4
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After invitro dissolution studies from MH1-MH4,CH1-CH4,CE1-CE4,HE1-HE4 it was 
observed that formulation CH4 showed least release since the polymers carbopol 940,HPMC 
holds the drug effectively,CH4 was choosen as the best formulation for controlled release of 
drug.
7. ANTIMICROBIAL STUDIES
Fig.15 :  Zone of Inhibition of Maltodextrin – HPMC(MH4)
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Fig.16 :  Zone of Inhibition of Carbopol 940 – HPMC(CH4)
Fig.17 : Zone of Inhibition of Carbopol 940 -Ehyl Cellulose(CE4)
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Fig.18 Zone of Inhibition of: HPMC - Ethyl Cellulose(HE4)
Results of Antimicrobial Study  :
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Table -18 : Zone of Inhibition of Formulations  MH4,CH4,CE4,HE4
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Fig.19 :Graph showing Zone of Inhibition of MH4,CH4,CE4,HE4
By antimicrobial studies  it was observed that  formulations MH4,CH4,CE4,HE4 showed 
zone of inhibition 13mm,14mm,16mm,15mm respectively indicating that these formulations 
are having  antifungal activity.
8.Drug Release Kinetics
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Formulation Zone of 
inhibition(mm)
MH4 13
CH4 14
CE4 16
HE4 15
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The in vitro drug release data were subjected to kinetic analysis by plotting various kinetic
equations  like  zero  order,  first  order,  Higuchi,  and  Hixon crowells  plot.  They were  also
subjected for peppas plot  in order to find out the mechanism of release from the prepared
tablets . The kinetic analysis data of all the formulations were shown in Table no 19.
The kinetic model that best fits with the release data of formulation was evaluated by the
correlation coiefficient (R2) values. According to the values obtained it was found that all the
formulations showed a higher linearity with zero order plots with R2 values ranging from
0.954  to  0.997  indicating  controlled  release  of  drug  from  the  prepared  formulation  .
Formulation MH-4, CH-4, CE-4 and HE-4 gave a best fit for  first order equation describing
drug release rate with concentration of drug.
Mechanism of drug release: 
Mechanism  of  drug  release  data  can  be  assist  by  plotting  the  drug  release  data  with
Koresmeyer-peppas equation.  The release  exponent (n)  value indicates  the mechanism of
drug transport from the matrix system. When the n value is equal to 0.5 indicates Fickian
diffusion or  anomalous, 0.45-0.89 indicates non-fickian transport more than 0.89 indicates
Super case II transport.
The slope values obtained from the formulation ranged from 0.896 to 1.088 revealed the fact
that  drug release follows super  case II  transport  diffussion posibly due to  polymer chain
errosion and swelling.
Table-19 :Results of drug release kinetics analysis
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Formulation
s
zero-
order
First-
order
Higuch
i
hixson-
crowell
korsmeyer-
peppas
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R2 R2 R2 R2 R2 n R2
MH1 0.954 0.962 0.956 0.987 0.974 0.986
MH2 0.995 0.953 0.96 0.985 0.952 0.994
MH3 0.991 0.946 0.978 0.979 0.898 0.995
MH4 0.992 0.982 0.987 0.958 0.932 0.998
CH1 0.934 0.861 0.986 0.905 0.896 0.985
CH2 0.98 0.874 0.992 0.927 0.971 0.992
CH3 0.997 0.927 0.978 0.968 1.005 0.998
CH4 0.991 0.972 0.978 0.977 1.022 0.995
CE1 0.997 0.942 0.974 0.975 0.949 0.995
CE2 0.996 0.942 0.969 0.978 1.024 0.995
CE3 0.983 0.953 0.952 0.984 1.063 0.99
CE4 0.984 0.962 0.957 0.979 1.088 0.978
HE1 0.992 0.949 0.962 0.98 1.025 0.989
HE2 0.983 0.953 0.952 0.984 1.063 0.99
HE3 0.985 0.957 0.951 0.979 0.961 0.976
HE4 0.996 0.964 0.977 0.965 1.032 0.995
9.Statistical Analysis :
DESIGN SUMMARY AND RESPONSES
Table 20 : Design summary and responses of Statistical Analysis
                                                                        Response
Formulation Factor-A Factor-B Hardness
Kg/cm2
Release 
at 1sthr in 
%
T50% 
in hrs
Zone of 
inhibition in mm
Dept of Pharmaceutics, KMCH College of Pharmacy, Coimbatore Page 80
                                                                            RESULTS AND DISCUSSION
MH4 -1 -1 5.4 12.27 7 12
CH4 1 1 5.5 6.35 8 14
CE4 -1 1 5.3 6.75 8 16
HE4 1 -1 5.3 8.25 8 15
RESULTS OF STATISTICAL ANALYSIS
Table 21 : ANOVA  Response for  Hardness  
Sum of
Squares df Mean Square F Sig.
Between Groups 20.799 2 10.400 0.031 0.227
Within Groups 1.125 1 1.125
Total 21.924 3
 Statistically significant at α < 0.05
Table 22 : ANOVA  Response for Release at 1st hour  
Sum of
Squares df Mean Square F Sig.
Between Groups 5.000 3 1.667 0.0025
Within Groups 0.000 0
Total 5.000 3
 Statistically significant at α < 0.05
Table 23 : ANOVA  Response for  T50% in hours
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Sum of
Squares df Mean Square F Sig.
Between Groups 0.750 3 0.250 0.0036
Within Groups 0.000 0
Total 0.750 3
 Statistically significant at α < 0.05
Table 24 : ANOVA Response for Zone of Inhibition 
Sum of
Squares df Mean Square F Sig.
Between Groups 0.028 3 0.009 0.225
Within Groups 0.000 0
Total 0.028 3
 Statistically significant at α < 0.05
Table 25 : comparison chart of predicted and actual values for optimized Formulation
Formulation
s
Hardness Release at 1 hr T50% in hr Zone  of
inhibition in mm
Optimized
formulation
Actua
l 
Predicte
d
Actua
l 
Predicte
d
Actua
l 
Predicte
d
Actua
l 
Predicte
d 
5.37 5.5 8.40 8.5 7.75 8.0 14.25 15.0
Effect of formulation variables on hardness of the tablet 
In  this  case hardness  of  the tablet  was  found to be significant  with  an  F value 0.031,
indicating adequate fitting of  the  22 factorial  model.  Both  factors  A,B were  found to  be
significantly effective on the hardness of the tablet.
Effect of formulation variables on release at 1st hour  
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The Fluconazole release  at  1st  hr  was found to be significant  with  a  F value of  0.0025,
indicates   adequate  fitting  to  22 factorial  model.  Both  factors  A,B  were  found  to  be
significantly effective on the release of  a tablet at 1st hour.
Effect of formulation variables on time required for T50% of drug release. 
The T50% was  found to  be  highly significant  with  an  F  value  of  0.0036 indicating the
adequate fitting of the 22  factorial model. Both  factors A,B were found to be significantly
effective on the time required for T50% of drug release.
Effect of formulation variables on zone of inhibition
The zone of inhibition was found to be not significant with the F value of 0.225, indicating
inadequate fitting of the 22 factorial model. Both factors A,B were found to be  not significant
indicating that both  polymers does not have any effect on zone of inhibition. 
comparison  of predicted and actual values for optimized Formulation
By comparing predicted and actual values it was observed that  optimized formulation(CH4)
was choosen  as the best formulation since it showed least deviation from that of predicted
values.
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                                              SUMMARY
The present study was aimed at  preparing a  tablet  containing fluconazole for  controlled
release  of  drug. Frequent  administration  can  be  avoided  by  administering  controlled
release drug delivery system.It may improve efficiency in treatment with reduction in total
dose  total  dose  and  also  avoid  dose  dumping.  By  using  Maltodextrin,HPMC,carbopol
940,Ethyl cellulose the release retardant was observed and  22  factorial design was made,16
formulations  were  prepared.All  the  formulation  showed  good  correlation  with
pharmacopoeial standard for tablet, invitro dissolution data showed controlled release pattern
for  all  the formulations.Formulations were optimized statistically and results  showed that
MH4,CH4,CE4,HE4 close value to the optimized parameters and CH4 was choosen as the
optimized formulation, since it showed least deviation from the predicted response. 
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                                                     CONCLUSION
The controlled drug delivery is a promising approach to achieve in vitro release of drug by
using  polymers  like  Maltodextrin,HPMC,Carbopol-940,Ethylcelluose.Combination  of
Carbopol 940 and HPMC had resulted in controlled drug release. A systematic study using a
22 factorial  design revealed that  by selecting a suitable composition of  carbopol 940 and
HPMC(CH4), the desired dissolution profile could be achieved. The optimized formulation
gave best  result  in  drug release  was in  accordance  with  the USP dissolution criteria  for
controlled  release tablet  for  Fluconazole.  prepared  formulations  were  showing  zero-order
release pattern.It could be used as once a day formulation. This can also reduce the over dose
effects  such  as  hallucinations  and  paranoid  behaviour. However,  appropriate  balancing
between various levels of the 2 polymers could be an imperative to acquire proper controlled
release. High degree of prognosis obtained using SPSS stastistics corroborates that it is quite
efficient in optimizing drug delivery systems that exhibit non-linearity in response.
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